Short Communication VAP Angioimmunoblastic Lymphadenopathy
Cite this article as:
Awidi, A.S., Tarawneh, M.S., Abu Khalaf, M.S. et al. Cancer Chemother. Pharmacol. (1983) 10: 221. doi:10.1007/BF00255768
Five patients, three males and two females, with angioimmunoblastic lymphadenopathy (AIL) are described. The two who received steroids had no response and died 2 and 6 months later. The three patients who received vincristine, adriamycin and prednisolone (VAP) went into remission early and are still in remission with a follow-up of 22–35 months. It is concluded that VAP is effective therapy in AIL.